A 160 mg long-acting propranolol capsule produced significantly lower mean peak blood levels compared to 160 mg once daily and 80 mg twice daily standard tablets, but maintained higher levels later.
I The whole blood concentrations of propranolol have been compared, over a 48 h period, in twelve healthy male volunteers dosed with a 160 mg long-acting capsule formulation (LA, United Kingdom patent application No. 23114/77) and three standard tablet regimens; 160 mg once a day (CP 160), 80 mg twice a day (CP80) and 40 mg four times a day (CP40). 2 The mean peak blood level for the long-acting formulation was significantly lower than that obtained with the 160 mg standard tablet. However, from 12 h on the mean levels for the long-acting formulation were higher. 3 The mean peak blood level for the long-acting formulation was significantly lower than that obtained with the 80 mg twice a day regimen and this difference was maintained up to 24 h. Thereafter, however, the situation was reversed. 4 The mean blood levels between 12 and 15 h were lower for the long-acting formulation when compared with the 40 mg four times a day regimen. At all other times, however, the observed levels were very similar.
McAinsh et al. (1978) studied Healthy (n=12). Long-acting propranolol capsule vs. Standard tablet regimens (160 mg once daily, 80 mg twice daily, 40 mg four times daily) was evaluated on Whole blood concentrations of propranolol. A 160 mg long-acting propranolol capsule produced significantly lower mean peak blood levels compared to 160 mg once daily and 80 mg twice daily standard tablets, but maintained higher levels later.